CATALYST PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: CATALYST PHARMACEUTICALS INC. - COMMON STOCK

24 Jul 2024 09:55:10 By NetDania Notify

Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada

24 Jul 2024 08:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CATALYST PHARMACEUTICALS INC. - COMMON STOCK

23 Jul 2024 10:55:07 By NetDania Notify

Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024

22 Jul 2024 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®

30 May 2024 13:41:21 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024

28 May 2024 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update

08 May 2024 16:16:20 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024

01 May 2024 08:00:01 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024

22 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

28 Mar 2024 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

27 Mar 2024 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

13 Mar 2024 07:55:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

05 Mar 2024 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

28 Feb 2024 18:03:23 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

27 Feb 2024 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

21 Feb 2024 09:00:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

14 Feb 2024 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering

09 Jan 2024 16:05:13 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

05 Jan 2024 08:02:06 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

04 Jan 2024 16:49:58 By Nasdaq GlobeNewswire